Business article - July 24, 2026
BII announces new initiative to accelerate drug discovery for cardiometabolic diseases
The Novo Nordisk Foundation is funding a new pan-European initiative to accelerate drug discovery and the development of next generation therapeutics for cardiometabolic diseases (CMDs).
In a new job - July 24, 2026
Elicera consolidates its management in Uppsala, recruitment of new CEO has started
The Board of Directors and the CEO assess that having a consolidated management team on site in Uppsala, close to the core operations, will provide the best conditions for continuing to build the organization required for the next phase and for advancing development programs, the company states.
Europe - July 23, 2026
Fresenius establishes venture fund of more than EUR 200 million
With an intended investment volume of more than EUR 200 million over the next 5 years, Fresenius Ventures targets growth fields adjacent to Fresenius’ existing strategic platforms (Bio)Pharma, MedTech, and Care Provision.
Acquisition - July 20, 2026
Samsung Biologics makes tender offer to acquire PolyPeptide Group
The offer values PolyPeptide's equity at approximately CHF 1.46 billion.
Careers article - July 19, 2026
NLS Profile Abroad: Thomas Karikari
Thomas Karikari’s career has taken him across three continents: from Ghana to the UK and Sweden, and then to the US. Now an Associate Professor at the University of Pittsburgh and one of Nature Index’s “rising stars in ageing research”, he is helping move Alzheimer’s blood biomarkers beyond individual markers and towards a more complete picture of disease biology.
The magazine - July 17, 2026
Summer greetings and top five articles of Q1 & Q2 2026
We would like to thank our readers, subscribers and collaboration partners for a fruitful and eventful Q1 + Q2 2026, and we wish you all a most wonderful summer!
